x
ServiziMenu principaleHome
You are here: Home > What we do > Past events > 2014 > Molecular Diagnostics, Genomics and Epigenetics in Clinical Oncology
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Description

Chairs: M.S. Aapro, CH  -  J. Gligorov, FR


The understanding of cancer biology and  development of specific  immunological and "targeted" treatments is revolutionizing cancer treatment. To optimize the use of these therapeutic advances there is a clear need to define the disease of the patient more precisely.

This event will try to find answers to questions such as which parameters are of importance for the evaluation of patient prognosis and prediction of efficacy of the treatment. The Faculty will explain what can be asked from new methods, what do they bring today and what will they bring tomorrow.


LEARNING OBJECTIVES
Update the knowledge on the implications for practice and clinical research (tools to be used, tools still in research, areas where no tools are yet available)
Understand epigenetics and genomics research and their impact on cancer prognosis and therapy response (prediction).




 The Board of ESO and Chairs of the Conference are with all their compassion near to the family and friends of a wonderful person, a great
 physician, John Fitzpatrick who passed away May 14. John will be remembered by us as THE champion of the older prostate cancer patients. 
 He defended their right for state of the art treatments with passion and science.



General information

ORGANISING SECRETARIAT
European School of Oncology (ESO)
Via Turati, 29
20121 - Milan, Italy

Programme and Organisation
Roberta Ventura -  rventura@eso.net - Tel: +39 02 85464532

VENUE
Radisson Blu ES. Hotel
Via Turati, 171 - Rome, Italy
Phone: +39 06 444 841
Website: www.radissonblu.com/eshotel-rome


OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.


INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance.


WI-FI ACCESS
Free Wi-Fi internet access in all areas of the conference venue is available.


FILMING, AUDIO-TAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.


REGISTRATION DESKS, OPENING HOURS
Friday, 28 November 8:00-17:00
Saturday, 29 November 8:00-13:00


EXHIBITION, OPENING HOURS
Friday, 28 November 8:00-17:00
Saturday, 29 November 8:00-13:00


SPONSORS
           

          
           
           

Faculty list


FACULTY
M.S. Aapro, IMO Clinique de Genolier, CH
S. Bracarda, San Donato Hospital, Arezzo, IT
F. Cappuzzo, Istituto Toscano Tumori, Livorno, IT
F. Ciardiello, Seconda Università degli Studi di Napoli, Naples, IT
F. Cognetti, Regina Elena National Cancer Institute, Rome, IT
R. Danesi, University of Pisa, IT
V. Dieras, Institut Curie, Paris, FR
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Paris, FR
L. Lacroix, Institut Gustave Roussy, Villejuif, FR
M. Lawler, Queen's University Belfast, UK
G. Pruneri, European Institute of Oncology, Milan, IT
J. Robert, Institut Bergonié, Bordeaux, FR
P. Romero, Centre Anticancéreux Jean Perrin, Clermont-Ferrand, FR
M. Roobol, Erasmus University Medical Centre, Rotterdam, NL
D. Rossi, Amedeo Avogadro University of Eastern Piedmont, Novara, IT
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
H.J. Schmoll, Martin Luther University, Halle, DE




.

Programme


28 November

   
9:00 Introduction
M.S. Aapro, CH - J. Gligorov, FR

9:15

 Personalized cancer medicine: are we there yet?
M. Lawler, UK
9:35 Discussion
9:45 Epigenetics and circulating tumor DNA: a frontier in cancer biology
R. Danesi, IT
10:05 Discussion
10:15 Pharmacogenomics: a key for proper treatment
J. Robert, FR
10:35 Discussion
10:45 Coffee break
 11:15 Next  generation sequencing genomic signatures
L. Lacroix, FR
 11:35 Discussion
WHERE DO WE STAND ON LUNG CANCER?

 11:45 Lung cancer as a model for the development of personalized medicine: what should you ask for in order to apply specific treatments
F. Cappuzzo, IT
 12:05
 Discussion
 12:15 Future developments in medical lung cancer therapy
E. Felip, ES
 12:35 Discussion
 12:45  Lunch
 14:00 Genomics: an essential aspect for hemato-oncologists
D. Rossi, IT
WHERE DO WE STAND ON COLORECTAL CANCER?

 14:30 
About k-ras, b-raf and beyond as predictive markers in mCRC
F. Ciardiello, IT
 14:50 Discussion
 15:00 How does the clinician use these data to best treat colon cancer?
H.J. Schmoll, DE 
 15:20 Discussion
 15:30 Coffee break

WHERE DO WE STAND ON PROSTATE CANCER?

 15:50 To screen or not to screen
M. Roobol, NL
 16:10 Discussion
 16:20
 Genomic tools in prostate cancer
S. Bracarda, IT
 16:40 Discussion
 16:50-17:00 Days's closure
M. Aapro, CH - J. Gligorov, FR
 17:15-18:15 Sponsored satellite symposium
Do genomic signatures provide the same information?

 

29 November

   
9:00 Introduction
M. Aapro, CH - J. Gligorov, FR  
WHERE DO WE STAND ON BREAST CANCER
9:10 Classic pathology of breast cancer: triple negatives with good prognosis and rare subtypes
P. Romero, FR

9:30
  Discussion
9:40   Molecular characterization of breast cancer: when is  it needed
G. Pruneri, IT
10:00  Discussion

10:10 Coffee break
10:40 Neoadjuvant therapy and beyond: applying data to the clinic
H. Rugo, US
11:10
  Discussion
 11:20 Treatment of triple negative disease in the adjuvant and metastatic settings:
is there a best therapy?
H. Rugo, US
 11:40  Discussion
 11:50 HER-2 positive
V. Dieras, FR
 12:10  Discussion

 12:20  Luminal A or B: not the same...
F. Cognetti, IT

 12:40 Discussion
 13:00 Close
   
   
   
   
   

 

« Back to "2014"